Radiomics received a visit from Mathieu Michel, State Secretary for Digitization

The Liège-based start-up is experiencing a real success story. It dynamically asserts its leadership position in the radiomics market and displays growth objectives and global ambitions."I have been very pleased to receive the visit of the State Secretary for Digitization and protection of privacy - said Wim Vos, CEO of Radiomics- These two themes concern us particularly, with our technology based on artificial intelligence being at the heart of digital personalized medicine. Protecting patient data is one of the major challenges for our patient-centered approach to be successful.The presence of   Mr. Marc Foidart, manager within Epimède and expert in setting up investment dossier for technological start-ups, particularly in Life Sciences, also made it possible to address questions on the financing of innovative companies in the sector. "

Founded in 2016 and based in Liège, Radiomics is a Belgian contract research organization (CRO) for next-generation image analysis, based on the unique experience of its founders, pioneers in radiomic science. Since its foundation, the company has diversified and greatly expanded its service offerings. Although oncology remains one of its priority areas, its objective is to develop radiomics applications in various therapeutic areas, thanks in particular to its potential in the respiratory field. Radiomics uses its advanced image analysis technology based on artificial intelligence (AI), deep learning and federated learning to uncover hidden information in standard medical images. Its goal is to support decision-making through insights and optimize pharmaceutical and biotech companies’ clinical trials and drug development studies and providing clinicians with a patient-centered approach based on personalized medicine.

Thanks to its dynamism, its accelerated growth and its promising future, Radiomics attracts highly qualified profiles in Liège and in Wallonia. Its young and energetic atmosphere is apt to attract ambitious graduates from Belgian and foreign universities.

From 5 people employed at the end of 2019, the company has grown to more than 30 people in the first quarter of 2021. And it will probably double its workforce over the next 24 months. Different profiles are sought: biomedical expert, radiologists, data manager, scientist specializing in artificial intelligence, scientist expert in visualization, software engineer, quality assurance manager, project manager, administrative and human resources assistant, and business developer, in particular for the American and Chinese markets. This year, the company will launch its first clinical product in the European and American markets.

Radiomics is in the process of securing up to 6 million euros funding for its first clinical study in lung cancer. To achieve this objective, the company can count on the support of its historical shareholders, including the Noshaq and Epimède funds, the DG06, its management and the banking sector.

The start-up is also developing ambitious international projects for which it benefits from the support of Sofinex (Walloon Export Financing Company), like the recent opening on May 1st of its first North American office in Toronto with support from the Walloon investment agency AWEX. As Carlos C. Meca, Chief Commercial Officer   points out, “With this establishment in North America, we want to approach the most promising markets in terms of technology. We also intend to achieve commercial projects in China from 2022”.

Radiomics, Clos Chanmurly, 13, 4000 Liège, 04/229 22 80,www.radiomics.bio,[email protected]